ClinicalTrials.gg
CompletedNCT02437318SOLAR-1Updated Feb 13, 2025Results posted

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

A Phase 3 interventional study of Fulvestrant and Alpelisib in Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 197 sites in 31 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-02-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
572
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 38 studies testing alpelisib in Breast Neoplasms — 3 open to participants now, 12 under way, 2 of them phase 3. Alpelisib · Breast Neoplasms.

Enrollment
Largest of 38
572 · median 44
Started
2015
with 2 others
Phase 3
5 of 38
none open now
Registered
16th of 38
by date
Lead sponsor
18 of 38
Novartis Pharmaceuticals

Among the 38 studies testing alpelisib in Breast Neoplasms, this one has the largest enrollment, is one of 3 that started in 2015, is one of 5 in phase 3, and was the 16th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

3 of the 38 studies testing alpelisib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About alpelisib

Alpelisib: first FDA approval 2019 (PIQRAY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing alpelisib in Breast Neoplasms, or all of them as a file.
02

Study summary

To determine whether treatment with alpelisib plus fulvestrant prolonged progression-free survival (PFS) compared to fulvestrant and placebo in men and postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor-2 (HER2)-negative advanced breast cancer, who received prior treatment with an aromatase Inhibitor (AI) either as (neo)adjuvant or for advanced disease.

Read the detailed description

This was a randomized, double-blind, placebo-controlled, international multicenter Phase III study that evaluated the efficacy and safety of treatment with alpelisib plus fulvestrant versus placebo plus fulvestrant in men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer which had progressed on or after AI treatment.

Subjects were allocated to either the PIK3CA mutant or PIK3CA non-mutant cohort, based on central testing of hotspot-mutations in tumor tissue. Subjects with unknown results were not eligible. Within each cohort, subjects were randomized in a 1:1 ratio to receive either alpelisib 300 mg orally once daily (q.d.), in combination with fulvestrant 500 mg intramuscular (i.m.) on Days 1 and 15 of Cycle 1 and Day 1 of a 28-day cycle thereafter, or placebo daily in combination with fulvestrant 500 mg following the same treatment regimen.

Subjects were treated until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason. All subjects who discontinued study treatment were followed for safety, until 30 days after last study treatment administration, except in the case of death, loss to follow-up, or withdrawal of consent.

Subjects who discontinued study treatment for reasons other than disease progression or withdrawal of consent, were followed until disease progression, death, withdrawal of consent, loss to follow-up, or subject/guardian decision (post-treatment efficacy follow-up).

Finally, all subjects were followed for survival after discontinuation of study treatment and tumor evaluations until the subject's death, loss to follow-up, or withdrawal of consent for survival follow-up (post-treatment survival follow-up)

03

Conditions studied

  • Breast Cancer

Keywords

  • BYL719
  • HR+
  • HER2-negative
  • advanced breast cancer
  • alpelisib
  • fulvestrant
  • PI3K
  • Phase III
  • ER+
  • PgR+
  • men
  • postmenopausal
  • aromatase inhibitor
  • neoplasms
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • If female, the patient was .
  • The patient had identified PIK3CA status.
  • Patients could be:
  • with documented evidence of progression while on (neo) endocrine therapy or within 12 months from completion of (neo)adjuvant endocrine therapy with no treatment for disease.
  • Relapsed with documented evidence of progression more than 12 months from completion of (neo)adjuvant endocrine therapy and then subsequently progressed with documented evidence of progression while on or after only one line of endocrine therapy for metastatic disease.
  • Newly diagnosed with advanced breast cancer, then relapsed with documented evidence of progression while on or after only one line of endocrine therapy.
  • The patient had recurrence or progression of the disease during or after AI therapy (i.e., letrozole, anastrozole, exemestane).
  • The patient had a and/or cytologically confirmed diagnosis of estrogen-receptor positive breast cancer by a local laboratory and had negative breast cancer.
  • The patient had either per 1.1 criteria or at least one predominantly lytic bone lesion present.
  • The patient had adequate bone marrow function.

Exclusion criteria

Exclusion Criteria:

  • The patient had symptomatic visceral disease or any disease burden that made the patient ineligible for endocrine therapy per the investigator's best judgment.
  • The patient had received prior treatment with chemotherapy (except for /adjuvant chemotherapy), fulvestrant, any PI3K, mTOR, or AKT inhibitor (pre-treatment with CDK4/6 inhibitors was allowed).
  • The patient had inflammatory breast cancer at screening.
  • Patients had score B or C.
  • Patients had an established diagnosis of diabetes mellitus type I or uncontrolled type II.
  • The patient had (ECOG) performance status 2 or more.
  • The patient had CNS involvement unless he/she was at least 4 weeks from prior therapy completion to starting the study treatment and had a stable CNS tumor at the time of screening and was not receiving and/or enzyme-inducing antiepileptic medications for .
  • The patient had participated in a prior study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever was longer.
  • The patient had a history of acute pancreatitis within 1 year of screening or a past medical history of chronic pancreatitis.
  • The patient with documented evidence of progression more than 12 months from completion of (neo)adjuvant endocrine therapy with no treatment for disease.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
572 participants (actual)

Study arms

  • Experimental
    Fulvestrant + alpelisib

    Subjects treated with alpelisib (300 mg; oral; once daily) in combination with fulvestrant (500 mg; intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle)

    Drug: Fulvestrant · Drug: Alpelisib

  • Placebo comparator
    Fulvestrant + placebo

    Subjects were treated with placebo (300 mg; oral; once daily) in combination with fulvestrant (500 mg; intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle)

    Drug: Fulvestrant · Drug: Placebo

Interventions

  • 500 mg of fulvestrant administered via intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle

  • 300 mg of alpelisib tablets for oral use administered once daily

    Also known as: BYL719

  • DrugPlacebo

    300 mg of placebo tablets for oral use administered once daily

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort

    PFS was defined as the time from the date of randomization to the date of the first documented progression or death due to any cause. PFS was assessed via a local radiology assessment according to RECIST 1.1. If a patient did not have an event, PFS was censored at the date of last adequate tumor assessment. The PFS distribution was estimated using Kaplan-Meier methodology. Progression was defined as at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months

Secondary outcomes

  1. Overall Survival (OS) in the PIK3CA Mutant Cohort

    OS was defined as the time from date of randomization to date of death due to any cause. If a patient was not known to have died, survival was censored at the date of last known date patient alive. The OS distribution was estimated using Kaplan-Meier methodology.

    Time frame: Once approximately 178 deaths in the PIK3CA mutant cohort had been observed, up to 55.7 months

  2. PFS Per Investigator Assessment in the PIK3CA Non-mutant Cohort

    PFS was defined as the time from the date of randomization to the date of the first documented progression or death due to any cause. PFS was assessed via a local radiology assessment according to RECIST 1.1. If a patient did not have an event, PFS was censored at the date of last adequate tumor assessment. The PFS distribution was estimated using Kaplan-Meier methodology. Progression was defined as at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: Up to 56.4 months

  3. OS in the PIK3CA Non-mutant Cohort

    OS was defined as the time from date of randomization to date of death due to any cause. If a patient was not known to have died, survival was censored at the date of last known date patient alive. The OS distribution was estimated using Kaplan-Meier methodology.

    Time frame: Up to 56.4 months

  4. Overall Response Rate (ORR) Per Investigator Assessment

    ORR was defined as the percentage of patients with best overall response of complete response (CR) or partial response (PR) based on local investigator's assessment according to RECIST 1.1. CR: Disappearance of all non-nodal target and non-target lesions. In addition, any pathological lymph nodes assigned as target and non-target lesions must have a reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.

    Time frame: Up to 56.4 months

  5. Clinical Benefit Rate (CBR) Per Investigator Assessment

    Clinical benefit rate was defined as the percentage of patients with a best overall response of CR or PR or stable disease (SD) or Non-CR/Non-PD lasting more than 24 weeks based on local investigator assessment according to RECIST 1.1. CR: Disappearance of all non-nodal target and non-target lesions. In addition, any pathological lymph nodes assigned as target and non-target lesions must have a reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.

    Time frame: Up to 56.4 months

  6. Time to Definitive Deterioration of Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Score From Baseline

    ECOG PS categorized patients based on their ability to perform daily activities and self-care, with scores ranging from 0 to 5. A score of 0 indicated no restrictions in activity, while higher scores indicated increasing limitations. Time to definitive deterioration of ECOG PS by one score was defined as the time from the date of randomization to the date of the event, defined as experiencing at least one score lower than the baseline. A deterioration was considered definitive if no improvements in the ECOG PS were observed at a subsequent time. The Kaplan-Meier method was used to estimate the distribution. Patients receiving any further therapy prior to definitive worsening were censored at their date of last assessment prior to start of therapy. Patients that had not worsened at the data cutoff point were censored at the date of last assessment.

    Time frame: From baseline up to 56.4 months

  7. Time to 10% Deterioration in the Global Health Status (GHS) /Quality of Life (QOL) Scale Score of the European Organization for Research and Treatment of Cancer's Core Quality of Life Questionnaire (EORTC QLQ-C30)

    The EORTC QLQ-C30 is a questionnaire that includes 5 functional scales, 3 symptom scales, 1 GHS/QoL scale, and 6 single items. GHS/QoL scale score ranges between 0 and 100. A high score for GHS/QoL represents better functioning or QoL.The time to definitive 10% deterioration was defined as the time from the date of randomization to the date of event, which was defined as at least 10% relative to baseline worsening of the GHS/QoL score (without further improvement above the threshold) or death due to any cause. The Kaplan-Meier method was used to estimate the distribution. If a patient had not had an event, time to deterioration was censored at the date of the last adequate QoL evaluation.

    Time frame: From baseline up to 55.7 months

  8. Change From Baseline in the GHS/QOL Scale Score of the EORTC QLQ-C30

    The EORTC QLQ-C30 is a questionnaire that includes 5 functional scales, 3 symptom scales, 1 GHS/QoL scale, and 6 single items. GHS/QoL scale score ranges between 0 and 100. A high score for GHS/QoL represents better functioning or QoL.The change from baseline in the GHS/QoL score was assessed. A positive change from baseline indicated improvement. For each cohort, this analysis only included assessments up to the time point where there were at least 10 patients on each of the 2 treatment groups.

    Time frame: Baseline, every 8 weeks after randomization during the first 18 months and thereafter every 12 weeks, up to 120 weeks.

  9. Trough Plasma Concentration of Alpelisib

    Pre-dose plasma concentrations of alpelisib were assessed. Only participants randomized to the alpelisib + fulvestrant arm were included in this analysis.

    Time frame: Day 8 and Day 15 of Cycle 1, then Day 1 of Cycles 2, 4, 6 and 8. Cycle = 28 days

  10. Trough Plasma Concentration of Fulvestrant

    Pre-dose plasma concentrations of fulvestrant were assessed.

    Time frame: Day 15 of Cycle 1, then Day 1 of Cycles 2, 4, 6 and 8. Cycle = 28 days

  11. PFS Per Investigator Criteria in Subjects With PIK3CA Mutation Status Measured in ctDNA at Baseline

    PFS was defined as the time from the date of randomization to the date of the first documented progression or death due to any cause. PFS was assessed via a local radiology assessment according to RECIST 1.1. If a patient did not have an event, PFS was censored at the date of last adequate tumor assessment. The PFS distribution was estimated using Kaplan-Meier methodology. Subjects were analyzed according to the PIK3CA mutation status (mutant or non-mutant) as identified using plasma ctDNA. Progression was defined as at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From baseline up to 56.4 months

Other outcomes

  1. Updated PFS Per Investigator Assessment in the PIK3CA Mutant Cohort (Longer Follow-up)

    PFS was defined as the time from the date of randomization to the date of the first documented progression or death due to any cause. PFS was assessed via a local radiology assessment according to RECIST 1.1. If a patient did not have an event, PFS was censored at the date of last adequate tumor assessment. The PFS distribution was estimated using Kaplan-Meier methodology. This analysis was conducted at the time of the final OS analysis (when approximately 178 deaths in the PIK3CA mutant cohort had been achieved) and includes a longer follow-up time. Progression was defined as at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: Up to 55.7 months

07

Results

Posted Aug 13, 2019

Participant flow

Participants were enrolled in 198 centers across 31 countries

Participant flow — Overall Study
MilestoneAlpelisib + FulvestrantPlacebo + Fulvestrant
Started284288
Treated284287
Pik3ca mutant cohort by tumor tissue169172
Pik3ca non-mutant cohort by tumor tissue115116
Pik3ca mutant cohort by ctdna9294
Pik3ca non-mutant cohort by ctdna181182
Completed00
Not completed284288
Withdrew: Progressive disease207240
Withdrew: Subject/guardian decision2411
Withdrew: Physician decision2922
Withdrew: Adverse event144
Withdrew: Death44
Withdrew: Protocol deviation57
Withdrew: Sponsor decision10

Outcome measures

PrimaryProgression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort

PFS was defined as the time from the date of randomization to the date of the first documented progression or death due to any cause. PFS was assessed via a local radiology assessment according to RECIST 1.1. If a patient did not have an event, PFS was censored at the date of last adequate tumor assessment. The PFS distribution was estimated using Kaplan-Meier methodology. Progression was defined as at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months
Reported as:
Median · Months
Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort
MonthsPIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + FulvestrantPIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant
Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort11.0 (7.49 to 14.52)5.7 (3.65 to 7.36)
Statistical analysis
  • PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant · Log Rank · p = 0.00065 ((one-sided)) · Hazard ratio (hr): 0.65 · 95% CI 0.50 to 0.85
SecondaryOverall Survival (OS) in the PIK3CA Mutant Cohort

OS was defined as the time from date of randomization to date of death due to any cause. If a patient was not known to have died, survival was censored at the date of last known date patient alive. The OS distribution was estimated using Kaplan-Meier methodology.

Time frame:
Once approximately 178 deaths in the PIK3CA mutant cohort had been observed, up to 55.7 months
Reported as:
Median · Months
Overall Survival (OS) in the PIK3CA Mutant Cohort
MonthsPIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + FulvestrantPIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant
Overall Survival (OS) in the PIK3CA Mutant Cohort39.3 (34.10 to 44.85)31.4 (26.78 to 41.30)
SecondaryPFS Per Investigator Assessment in the PIK3CA Non-mutant Cohort

PFS was defined as the time from the date of randomization to the date of the first documented progression or death due to any cause. PFS was assessed via a local radiology assessment according to RECIST 1.1. If a patient did not have an event, PFS was censored at the date of last adequate tumor assessment. The PFS distribution was estimated using Kaplan-Meier methodology. Progression was defined as at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
Up to 56.4 months
Reported as:
Median · Months
PFS Per Investigator Assessment in the PIK3CA Non-mutant Cohort
MonthsPIK3CA Non-mutant Cohort by Tumor Tissue: Alpelisib + FulvestrantPIK3CA Non-mutant Cohort by Tumor Tissue: Placebo + Fulvestrant
PFS Per Investigator Assessment in the PIK3CA Non-mutant Cohort7.43 (5.55 to 10.84)7.23 (5.06 to 9.17)
SecondaryOS in the PIK3CA Non-mutant Cohort

OS was defined as the time from date of randomization to date of death due to any cause. If a patient was not known to have died, survival was censored at the date of last known date patient alive. The OS distribution was estimated using Kaplan-Meier methodology.

Time frame:
Up to 56.4 months
Reported as:
Median · Months
OS in the PIK3CA Non-mutant Cohort
MonthsPIK3CA Non-mutant Cohort by Tumor Tissue: Alpelisib + FulvestrantPIK3CA Non-mutant Cohort by Tumor Tissue: Placebo + Fulvestrant
OS in the PIK3CA Non-mutant Cohort37.29 (27.89 to 45.47)34.30 (26.81 to 39.03)
SecondaryOverall Response Rate (ORR) Per Investigator Assessment

ORR was defined as the percentage of patients with best overall response of complete response (CR) or partial response (PR) based on local investigator's assessment according to RECIST 1.1. CR: Disappearance of all non-nodal target and non-target lesions. In addition, any pathological lymph nodes assigned as target and non-target lesions must have a reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.

Time frame:
Up to 56.4 months
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR) Per Investigator Assessment
Percentage of participantsPIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + FulvestrantPIK3CA Mutant Cohort by Tumor Tissue: Placebo + FulvestrantPIK3CA Non-mutant Cohort by Tumor Tissue: Alpelisib + FulvestrantPIK3CA Non-mutant Cohort by Tumor Tissue: Placebo + Fulvestrant
Overall Response Rate (ORR) Per Investigator Assessment26.6 (20.1 to 34.0)13.4 (8.7 to 19.4)20.9 (13.9 to 29.4)12.9 (7.4 to 20.4)
SecondaryClinical Benefit Rate (CBR) Per Investigator Assessment

Clinical benefit rate was defined as the percentage of patients with a best overall response of CR or PR or stable disease (SD) or Non-CR/Non-PD lasting more than 24 weeks based on local investigator assessment according to RECIST 1.1. CR: Disappearance of all non-nodal target and non-target lesions. In addition, any pathological lymph nodes assigned as target and non-target lesions must have a reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.

Time frame:
Up to 56.4 months
Reported as:
Number · Percentage of participants
Clinical Benefit Rate (CBR) Per Investigator Assessment
Percentage of participantsPIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + FulvestrantPIK3CA Mutant Cohort by Tumor Tissue: Placebo + FulvestrantPIK3CA Non-mutant Cohort by Tumor Tissue: Alpelisib + FulvestrantPIK3CA Non-mutant Cohort by Tumor Tissue: Placebo + Fulvestrant
Clinical Benefit Rate (CBR) Per Investigator Assessment61.5 (53.8 to 68.9)44.8 (37.2 to 52.5)53.9 (44.4 to 63.2)49.1 (39.7 to 58.6)
SecondaryTime to Definitive Deterioration of Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Score From Baseline

ECOG PS categorized patients based on their ability to perform daily activities and self-care, with scores ranging from 0 to 5. A score of 0 indicated no restrictions in activity, while higher scores indicated increasing limitations. Time to definitive deterioration of ECOG PS by one score was defined as the time from the date of randomization to the date of the event, defined as experiencing at least one score lower than the baseline. A deterioration was considered definitive if no improvements in the ECOG PS were observed at a subsequent time. The Kaplan-Meier method was used to estimate the distribution. Patients receiving any further therapy prior to definitive worsening were censored at their date of last assessment prior to start of therapy. Patients that had not worsened at the data cutoff point were censored at the date of last assessment.

Time frame:
From baseline up to 56.4 months
Reported as:
Median · Months
Time to Definitive Deterioration of Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Score From Baseline
MonthsPIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + FulvestrantPIK3CA Mutant Cohort by Tumor Tissue: Placebo + FulvestrantPIK3CA Non-mutant Cohort by Tumor Tissue: Alpelisib + FulvestrantPIK3CA Non-mutant Cohort by Tumor Tissue: Placebo + Fulvestrant
Time to Definitive Deterioration of Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Score From Baseline34.07 (26.32 to NA)NA (22.11 to NA)NA (13.83 to NA)40.44 (18.46 to 47.21)
SecondaryTime to 10% Deterioration in the Global Health Status (GHS) /Quality of Life (QOL) Scale Score of the European Organization for Research and Treatment of Cancer's Core Quality of Life Questionnaire (EORTC QLQ-C30)

The EORTC QLQ-C30 is a questionnaire that includes 5 functional scales, 3 symptom scales, 1 GHS/QoL scale, and 6 single items. GHS/QoL scale score ranges between 0 and 100. A high score for GHS/QoL represents better functioning or QoL.The time to definitive 10% deterioration was defined as the time from the date of randomization to the date of event, which was defined as at least 10% relative to baseline worsening of the GHS/QoL score (without further improvement above the threshold) or death due to any cause. The Kaplan-Meier method was used to estimate the distribution. If a patient had not had an event, time to deterioration was censored at the date of the last adequate QoL evaluation.

Time frame:
From baseline up to 55.7 months
Reported as:
Median · Months
Time to 10% Deterioration in the Global Health Status (GHS) /Quality of Life (QOL) Scale Score of the European Organization for Research and Treatment of Cancer's Core Quality of Life Questionnaire (EORTC QLQ-C30)
MonthsPIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + FulvestrantPIK3CA Mutant Cohort by Tumor Tissue: Placebo + FulvestrantPIK3CA Non-mutant Cohort by Tumor Tissue: Alpelisib + FulvestrantPIK3CA Non-mutant Cohort by Tumor Tissue: Placebo + Fulvestrant
Time to 10% Deterioration in the Global Health Status (GHS) /Quality of Life (QOL) Scale Score of the European Organization for Research and Treatment of Cancer's Core Quality of Life Questionnaire (EORTC QLQ-C30)18.14 (14.55 to 28.68)19.98 (11.50 to 25.59)7.39 (5.62 to NA)9.23 (3.94 to 13.17)
SecondaryChange From Baseline in the GHS/QOL Scale Score of the EORTC QLQ-C30

The EORTC QLQ-C30 is a questionnaire that includes 5 functional scales, 3 symptom scales, 1 GHS/QoL scale, and 6 single items. GHS/QoL scale score ranges between 0 and 100. A high score for GHS/QoL represents better functioning or QoL.The change from baseline in the GHS/QoL score was assessed. A positive change from baseline indicated improvement. For each cohort, this analysis only included assessments up to the time point where there were at least 10 patients on each of the 2 treatment groups.

Time frame:
Baseline, every 8 weeks after randomization during the first 18 months and thereafter every 12 weeks, up to 120 weeks.
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in the GHS/QOL Scale Score of the EORTC QLQ-C30
Score on a ScalePIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + FulvestrantPIK3CA Mutant Cohort by Tumor Tissue: Placebo + FulvestrantPIK3CA Non-mutant Cohort by Tumor Tissue: Alpelisib + FulvestrantPIK3CA Non-mutant Cohort by Tumor Tissue: Placebo + Fulvestrant
Week 8-2.477 ± 2.286-0.369 ± 2.3241.524 ± 2.5782.698 ± 2.601
Week 16-1.796 ± 2.349-2.685 ± 2.4552.866 ± 2.8091.700 ± 2.835
Week 24-3.010 ± 2.415-0.337 ± 2.5871.383 ± 3.0874.909 ± 3.385
Week 32-2.802 ± 2.519-0.891 ± 2.6461.063 ± 3.4204.345 ± 3.731
Week 40-2.815 ± 2.581-1.854 ± 2.73913.232 ± 4.7834.923 ± 4.003
Week 48-3.635 ± 2.621-1.460 ± 2.853——
Week 56-1.617 ± 2.7010.248 ± 2.935——
Week 64-1.937 ± 2.835-1.979 ± 2.984——
Week 72-2.525 ± 2.823-1.526 ± 3.098——
Week 84-1.135 ± 2.958-1.495 ± 3.143——
Week 96-3.869 ± 3.054-3.581 ± 3.423——
Week 108-2.158 ± 3.328-2.068 ± 3.609——
Week 120-2.928 ± 3.251-2.593 ± 3.868——
SecondaryTrough Plasma Concentration of Alpelisib

Pre-dose plasma concentrations of alpelisib were assessed. Only participants randomized to the alpelisib + fulvestrant arm were included in this analysis.

Time frame:
Day 8 and Day 15 of Cycle 1, then Day 1 of Cycles 2, 4, 6 and 8. Cycle = 28 days
Reported as:
Geometric mean · nanogram (ng)/ milliliter (mL)
Trough Plasma Concentration of Alpelisib
nanogram (ng)/ milliliter (mL)Alpelisib + Fulvestrant
Cycle 1 Day 8424 ± 41.1
Cycle 1 Day 15468 ± 57.6
Cycle 2 Day 1436 ± 53.4
Cycle 4 Day 1458 ± 69.4
Cycle 6 Day 1418 ± 57.1
Cycle 8 Day 1469 ± 58.3
SecondaryTrough Plasma Concentration of Fulvestrant

Pre-dose plasma concentrations of fulvestrant were assessed.

Time frame:
Day 15 of Cycle 1, then Day 1 of Cycles 2, 4, 6 and 8. Cycle = 28 days
Reported as:
Geometric mean · nanogram (ng)/ milliliter (mL)
Trough Plasma Concentration of Fulvestrant
nanogram (ng)/ milliliter (mL)Alpelisib + FulvestrantPlacebo + Fulvestrant
Cycle 1 Day 1510.8 ± 43.510.3 ± 51.0
Cycle 2 Day 114.0 ± 39.714.7 ± 41.2
Cycle 4 Day 111.5 ± 32.212.2 ± 29.8
Cycle 6 Day 112.6 ± 30.514.0 ± 24.2
Cycle 8 Day 113.5 ± 35.214.7 ± 23.2
SecondaryPFS Per Investigator Criteria in Subjects With PIK3CA Mutation Status Measured in ctDNA at Baseline

PFS was defined as the time from the date of randomization to the date of the first documented progression or death due to any cause. PFS was assessed via a local radiology assessment according to RECIST 1.1. If a patient did not have an event, PFS was censored at the date of last adequate tumor assessment. The PFS distribution was estimated using Kaplan-Meier methodology. Subjects were analyzed according to the PIK3CA mutation status (mutant or non-mutant) as identified using plasma ctDNA. Progression was defined as at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From baseline up to 56.4 months
Reported as:
Median · Months
PFS Per Investigator Criteria in Subjects With PIK3CA Mutation Status Measured in ctDNA at Baseline
MonthsPIK3CA Mutant Determined by ctDNA: Alpelisib + FulvestrantPIK3CA Mutant Determined by ctDNA: Placebo + FulvestrantPIK3CA Non-mutant Determined by ctDNA: Alpelisib + FulvestrantPIK3CA Non-mutant Determined by ctDNA: Placebo + Fulvestrant
PFS Per Investigator Criteria in Subjects With PIK3CA Mutation Status Measured in ctDNA at Baseline10.9 (7.03 to 15.28)3.7 (2.27 to 6.11)9.0 (7.23 to 11.01)7.4 (5.55 to 9.20)
Post-hocAll Collected Deaths

Pre-treatment deaths were collected from randomization to the day before first dose of study medication. On-treatment deaths were collected from start of treatment to 30 days after last dose of study medication. Post-treatment survival follow-up deaths were collected from day 31 after last dose of study treatment to end of study.

Time frame:
Pre-treatment: Up to 35 days. On-treatment: Up to approx. 6.5 years. Post-treatment survival follow-up: Up to approx. 6.5 years
Reported as:
Number · Participants
All Collected Deaths
ParticipantsAlpelisib + FulvestrantPlacebo + Fulvestrant
Pre-treatment00
On-treatment912
Post-treatment survival follow-up151156
All deaths160168
Other pre-specifiedUpdated PFS Per Investigator Assessment in the PIK3CA Mutant Cohort (Longer Follow-up)

PFS was defined as the time from the date of randomization to the date of the first documented progression or death due to any cause. PFS was assessed via a local radiology assessment according to RECIST 1.1. If a patient did not have an event, PFS was censored at the date of last adequate tumor assessment. The PFS distribution was estimated using Kaplan-Meier methodology. This analysis was conducted at the time of the final OS analysis (when approximately 178 deaths in the PIK3CA mutant cohort had been achieved) and includes a longer follow-up time. Progression was defined as at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
Up to 55.7 months
Reported as:
Median · Months
Updated PFS Per Investigator Assessment in the PIK3CA Mutant Cohort (Longer Follow-up)
MonthsPIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + FulvestrantPIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant
Updated PFS Per Investigator Assessment in the PIK3CA Mutant Cohort (Longer Follow-up)10.97 (7.49 to 14.52)5.65 (3.65 to 7.36)

Adverse events

Collected over All-cause mortality: from randomization up to approx. 6.5 years, including post-treatment survival follow up period. Serious and Other Adverse Events: from first dose of study treatment until 30 days after last dose up to approx. 6.5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alpelisib + Fulvestrant9/284 (3.2%)110/284 (38.7%)280/284 (98.6%)
Placebo + Fulvestrant12/288 (4.2%)54/287 (18.8%)244/287 (85%)
Alpelisib + Fulvestrant (Post-treatment Survival Follow-up)151/275 (54.9%)——
Placebo + Fulvestrant (Post-treatment Survival Follow-up)156/275 (56.7%)——
Most frequent serious events
Showing 10 of 147
Most frequent serious events
EventAlpelisib + FulvestrantPlacebo + FulvestrantAlpelisib + Fulvestrant (Post-treatment Survival Follow-up)Placebo + Fulvestrant (Post-treatment Survival Follow-up)
HyperglycaemiaMetabolism and nutrition disorders28/2840/287——
DiarrhoeaGastrointestinal disorders9/2840/287——
Osteonecrosis of jawMusculoskeletal and connective tissue disorders9/2842/287——
AnaemiaBlood and lymphatic system disorders6/2840/287——
Abdominal painGastrointestinal disorders6/2842/287——
Acute kidney injuryRenal and urinary disorders6/2841/287——
PneumoniaInfections and infestations3/2846/287——
NauseaGastrointestinal disorders5/2842/287——
VomitingGastrointestinal disorders5/2843/287——
RashSkin and subcutaneous tissue disorders5/2840/287——
Most frequent other events
Showing 10 of 50
Most frequent other events
EventAlpelisib + FulvestrantPlacebo + FulvestrantAlpelisib + Fulvestrant (Post-treatment Survival Follow-up)Placebo + Fulvestrant (Post-treatment Survival Follow-up)
HyperglycaemiaMetabolism and nutrition disorders182/28427/287——
DiarrhoeaGastrointestinal disorders167/28448/287——
NauseaGastrointestinal disorders133/28464/287——
Decreased appetiteMetabolism and nutrition disorders103/28430/287——
RashSkin and subcutaneous tissue disorders101/28420/287——
VomitingGastrointestinal disorders80/28427/287——
Weight decreasedInvestigations79/2847/287——
FatigueGeneral disorders73/28451/287——
StomatitisGastrointestinal disorders70/28420/287——
AstheniaGeneral disorders64/28440/287——

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Alpelisib + FulvestrantPlacebo + FulvestrantTotal
Mean62.6 ± 9.7463.3 ± 10.2663.0 ± 10.00
Sex: Female, Male
Sex: Female, Male(Participants)Alpelisib + FulvestrantPlacebo + FulvestrantTotal
Female283288571
Male101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Alpelisib + FulvestrantPlacebo + FulvestrantTotal
White199178377
Asian5966125
Black or African American268
American Indian or Alaska145
Other91726
Unknown141731
08

Study locations

197 sites
  • Ironwood Cancer and Research Centers
    Chandler, Arizona 85224, United States
  • Mayo Clinic Arizona
    Scottsdale, Arizona 85259, United States
  • Highlands Oncology Group
    Fayetteville, Arkansas 72703, United States
  • Beverly Hills Cancer Center
    Beverly Hills, California 90211, United States
  • City of Hope National Medical Center
    Duarte, California 91010 3000, United States
  • Scripps Green Hospital
    La Jolla, California 92037, United States
  • Kaiser Permanent Southern Californi
    San Diego, California 92120, United States
  • UCSF
    San Francisco, California 94115, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33901, United States
  • Florida Cancer Specialists-North
    Saint Petersburg, Florida 33705, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • NorthShore University Health System
    Evanston, Illinois 60201, United States
  • Edward Cancer Center
    Naperville, Illinois 60540, United States
  • Fort Wayne Medical Oncology Hematology Inc
    Fort Wayne, Indiana 46815, United States
  • St Francis Health Comprehensive Cancer Center
    Topeka, Kansas 66606-169, United States
  • Mercy Medical Center
    Baltimore, Maryland 21202, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Lahey Clinic
    Burlington, Massachusetts 01805, United States
  • Detroit Clinical Research Center
    Owosso, Michigan 48867, United States
  • St Lukes Cancer Institute
    Kansas City, Missouri 64111, United States
  • St Vincent Frontier Cancer Center
    Billings, Montana 59102, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08903, United States
  • University Hospitals of Cleveland Seidman Cancer Center
    Cleveland, Ohio 44106, United States
  • Good Samaritan Regional Medical Center
    Corvallis, Oregon 97330, United States
  • Lancaster General Hospital
    Lancaster, Pennsylvania 17604, United States
  • Prisma Health Upstate
    Greenville, South Carolina 29615, United States
  • Avera Cancer
    Sioux Falls, South Dakota 57105, United States
  • SCRI Oncology Partners
    Nashville, Tennessee 37203, United States
  • Texas Oncology PA Dallas Presbyterian Hospital
    Dallas, Texas 75231, United States
  • El Paso Texas Oncology
    El Paso, Texas 79902, United States
  • Mays Cancer Ctr Uthsa Mdacc
    San Antonio, Texas 78229, United States
  • Texas Oncology Northeast Texas
    Tyler, Texas 75702, United States
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
  • Wenatchee Valley Medical Center
    Wenatchee, Washington 98801, United States
  • Novartis Investigative Site
    Berazategui, Buenos Aires B1884BBF, Argentina
  • Novartis Investigative Site
    Caba, Buenos Aires C1125ABD, Argentina
  • Novartis Investigative Site
    Rio Negro, Viedma 8500, Argentina
  • Novartis Investigative Site
    La Rioja, 5300, Argentina
  • Novartis Investigative Site
    Wahroonga, New South Wales 2076, Australia
  • Novartis Investigative Site
    Wooloongabba, Queensland 4102, Australia
  • Novartis Investigative Site
    Elizabeth Vale, South Australia 5112, Australia
  • Novartis Investigative Site
    Melbourne, Victoria 3000, Australia
  • Novartis Investigative Site
    Linz, 4010, Austria
  • Novartis Investigative Site
    Wien, 1090, Austria
  • Novartis Investigative Site
    Sint Niklaas, Oost Vlaanderen 9100, Belgium
  • Novartis Investigative Site
    Brussel, 1090, Belgium
  • Novartis Investigative Site
    Bruxelles, 1000, Belgium
  • Novartis Investigative Site
    Edegem, 2650, Belgium
  • Novartis Investigative Site
    Libramont, 6800, Belgium
  • Novartis Investigative Site
    Ottignies, 1340, Belgium
  • Novartis Investigative Site
    Verviers, 4800, Belgium
  • Novartis Investigative Site
    Natal, RN 59075 740, Brazil
  • Novartis Investigative Site
    Lajeado, RS 95900-000, Brazil
  • Novartis Investigative Site
    Sao Paulo, SP 04014-002, Brazil
  • Novartis Investigative Site
    Sao Jose do Rio Preto, 15090 000, Brazil
  • Novartis Investigative Site
    Sao Paulo, 01236 030, Brazil
  • Novartis Investigative Site
    Plovdiv, 4004, Bulgaria
  • Novartis Investigative Site
    Sofia, 1756, Bulgaria
  • Novartis Investigative Site
    Varna, 9002, Bulgaria
  • Novartis Investigative Site
    Varna, 9010, Bulgaria
  • Novartis Investigative Site
    Calgary, Alberta T2N 4N2, Canada
  • Novartis Investigative Site
    Cambridge, Ontario N1R 3G2, Canada
  • Novartis Investigative Site
    Ottawa, Ontario K1H 8L6, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5B 1W8, Canada
  • Novartis Investigative Site
    Quebec, G1S 4L8, Canada
  • Novartis Investigative Site
    Temuco, Araucania 4810469, Chile
  • Novartis Investigative Site
    Santiago, 8420383, Chile
  • Novartis Investigative Site
    Vina del Mar, 2520612, Chile
  • Novartis Investigative Site
    Praha 4, Czech Republic 140 46, Czechia
  • Novartis Investigative Site
    Zlin, Czech Republic 762 75, Czechia
  • Novartis Investigative Site
    Hradec Kralove, CZE 500 05, Czechia
  • Novartis Investigative Site
    Prague 8, 180 00, Czechia
  • Novartis Investigative Site
    Marseille cedex 20, Bouches Du Rhone 13915, France
  • Novartis Investigative Site
    Angers 02, 49055, France
  • Novartis Investigative Site
    Avignon, 84082, France
  • Novartis Investigative Site
    Caen, 14021, France
  • Novartis Investigative Site
    Clermont-Ferrand, 63011, France
  • Novartis Investigative Site
    Creteil, 94010, France
  • Novartis Investigative Site
    La Roche sur Yon cedex 9, 85925, France
  • Novartis Investigative Site
    Le Chesnay, 78150, France
  • Novartis Investigative Site
    Levallois Perret, 92309, France
  • Novartis Investigative Site
    Lyon 08, 69373, France
  • Novartis Investigative Site
    Montpellier, 34070, France
  • Novartis Investigative Site
    Nimes, 30029, France
  • Novartis Investigative Site
    Rouen, 76038, France
  • Novartis Investigative Site
    Saint Herblain, 44805, France
  • Novartis Investigative Site
    Toulouse, 31059, France
  • Novartis Investigative Site
    Villejuif, 94800, France
  • Novartis Investigative Site
    Luebeck, Schleswig-Holstein 23563, Germany
  • Novartis Investigative Site
    Aschaffenburg, 63739, Germany
  • Novartis Investigative Site
    Frankfurt, 60389, Germany
  • Novartis Investigative Site
    Friedrichshafen, 88045, Germany
  • Novartis Investigative Site
    Hannover, 30625, Germany
  • Novartis Investigative Site
    Homburg, 66421, Germany
  • Novartis Investigative Site
    Kiel, 24105, Germany
  • Novartis Investigative Site
    Leipzig, 04277, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Potsdam, 14467, Germany
  • Novartis Investigative Site
    Recklinghausen, 45657, Germany
  • Novartis Investigative Site
    Rostock, 18059, Germany

Showing the first 100 of 197 sites across 31 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ciruelos EM, Rugo HS, Mayer IA, Levy C, Forget F, Delgado Mingorance JI, Safra T, Masuda N, Park YH, Juric D, Conte P, Campone M, Loibl S, Iwata H, Zhou X, Park J, Ridolfi A, Lorenzo I, Andre F. Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1. J Clin Oncol. 2021 Jun 20;39(18):2005-2015. doi: 10.1200/JCO.20.01139. Epub 2021 Mar 29. PubMed 33780274 ↗
  • Andre F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, Rubovszky G, Yamashita T, Kaufman B, Lu YS, Inoue K, Papai Z, Takahashi M, Ghaznawi F, Mills D, Kaper M, Miller M, Conte PF, Iwata H, Rugo HS. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021 Feb;32(2):208-217. doi: 10.1016/j.annonc.2020.11.011. Epub 2020 Nov 25. PubMed 33246021 ↗
  • Rugo HS, Andre F, Yamashita T, Cerda H, Toledano I, Stemmer SM, Jurado JC, Juric D, Mayer I, Ciruelos EM, Iwata H, Conte P, Campone M, Wilke C, Mills D, Lteif A, Miller M, Gaudenzi F, Loibl S. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol. 2020 Aug;31(8):1001-1010. doi: 10.1016/j.annonc.2020.05.001. Epub 2020 May 13. PubMed 32416251 ↗
  • Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Papai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D; SOLAR-1 Study Group. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019 May 16;380(20):1929-1940. doi: 10.1056/NEJMoa1813904. PubMed 31091374 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Jun 2018, 34 months.

Results were first posted in Aug 2019, 1 year 2 months after primary completion. A results delay was requested in Jul 2018.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 34 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2015
First posted
May 7, 2015
StartActual
Jul 23, 2015
Primary completionActual
Jun 12, 2018
CompletionActual
Jun 9, 2023
Results delay requested
Jul 24, 2018
Results first posted
Aug 13, 2019
Last update
Feb 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02437318
Responsible party
Sponsor
First posted
May 7, 2015
Start date
Jul 23, 2015
Primary completion
Jun 12, 2018
Completion
Jun 9, 2023
Results posted
Aug 13, 2019
Last update
Feb 13, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpelisib

Start the discussion